Table 2.

Clinical trials of combination of AA and other therapies.

Trial	PD-L1 assay	Phase	Histology	Design	PD-L1 status	ORR (%)	Median PFS (months) (HR, 95% CI)	Median OS (months) (HR, 95% CI)	≥3 TRAE
IMpower150	SP142	III	Nsq	ABCP (WT 356) BCP (WT 336)	TC 0/1/2/3 IC 0/1/2/3	63.5% vs. 48.0%	8.3 vs. 6.8 (HR 0.62; 0.52–0.74)	19.5 vs. 14.7 (HR 0.80; 0.67–0.95)	58.5% vs. 50.0%
					TC3 or IC3 (subgroup)	–	15.2 vs. 6.8 (HR 0.34; 0.23–0.50)	30.0 vs. 15.0 (HR 0.70; 0.46–1.08)
					TC1/2/3 or IC1/2/3 (subgroup)	–	11.1 vs. 6.8 (HR 0.47; 0.38–0.60)	22.5 vs. 16.0 (HR 0.73; 0.57–0.94)
					TC0 and IC0 (subgroup)	–	7.2 vs. 6.9 (HR 0.71; 0.57–0.89)	16.9 vs. 14.1 (HR 0.90; 0.71–1.14)
LEAP 007	Dako22C3	III	Nsq/sq	Pembro + lenva (309) Pembro (314)	TPS ≥1%	40.5% vs. 27.7%	6.6 vs. 4.2 (HR 0.78; 0.64–0.95)	14.1 vs. 16.4 (HR 1.10; 0.87–1.39)	57.9% vs. 24.4%

AA: Anti-angiogenic; ABCP: Atezolizumab plus BCP; BCP: Bevacizumab plus carboplatin plus paclitaxel; CI: Confidence interval; EGFR: Epidermal growth factor receptor; HR: Hazard ratio; IC: Immune cells; lenva: Lenvatinib; NR: Not reached; NSCLC: Non-small cell lung cancer; nsq: Non-squamous NSCLC; ORR: Objective response rate; OS: Overall survival; PD-1: Programed cell death protein 1; PD-L1: Programed cell death ligand 1; pembro: Pembrolizumab; PFS: Progression-free survival; sq: Squamous NSCLC; TC: Tumor cell; TPS: Tumor proportion score; TRAE: Treatment related adverse events; WT: EGFR or ALK wild type. “–” represents unavailability of data. TC3 or IC3: PD-L1 expression on ≥50% of TC or on ≥10% of IC; TC2/3 or IC2/3: PD-L1 expression on ≥5% of TC or IC; TC1/2/3 or IC1/2/3: PD-L1 expression on ≥1% of TC or IC. TC0 and IC0: PD-L1 expression on <1% of TC and IC.